Lin Yu-Hsin, the Chief Executive Officer of Belite Bio, Inc., has recently vested 5,000 ordinary shares following the achievement of specific performance criteria. This transaction, reported in a recent SEC filing, underscores the company's commitment to incentivizing its leadership and aligning their interests with those of shareholders.

Background

Belite Bio, Inc. operates within the pharmaceutical preparations industry, focusing on innovative solutions in life sciences. The company is based in San Diego, California, and has been active in filing important disclosures with the SEC, including recent forms that highlight significant transactions by its executives.

What the Filing Says

The SEC filing dated October 30, 2026, indicates that Lin Yu-Hsin was granted an award of restricted stock units (RSUs) on September 15, 2025. These RSUs vested on October 29, 2026, as certain performance criteria were met, allowing Yu-Hsin to acquire 5,000 ordinary shares. The filing states, "Certain of these performance criteria were met on 10/29/2026, resulting in vesting of the RSUs as to 5,000 ordinary shares." Following this transaction, Yu-Hsin now holds a total of 187,949 shares.

Impact

This development may influence various stakeholders, including shareholders and potential investors, as it demonstrates the company's focus on performance-based rewards. Such actions are crucial in the pharmaceutical preparations sector, where retaining top talent is essential for driving innovation and maintaining competitive advantage.

What's Next

The filing does not say what happens next.